Search

Your search keyword '"Villa, Maria Rosaria"' showing total 14 results
Start Over Author "Villa, Maria Rosaria" Search Limiters Full Text
14 results on '"Villa, Maria Rosaria"'

1. Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis

Author

Pugliese, Novella, primary, Giordano, Claudia, additional, Nappi, Davide, additional, Luciano, Luigiana, additional, Cerchione, Claudio, additional, Annunziata, Mario, additional, Casale, Beniamino, additional, Crisà, Elena, additional, Villa, Maria Rosaria, additional, Pezzullo, Luca, additional, Iovine, Maria, additional, Picardi, Marco, additional, Grimaldi, Francesco, additional, Pane, Fabrizio, additional, and Martinelli, Vincenzo, additional

Published
2019
Full Text
View/download PDF

2. Adding Hydroxyurea in Combination with Ruxolitinib Improves Clinical Responses in Hyperproliferative Forms of Myelofibrosis

Author

Pugliese, Novella, primary, Giordano, Claudia, additional, Nappi, Davide, additional, Luciano, Luigia, additional, Cerchione, Claudio, additional, Annunziata, Mario, additional, Casale, Beniamino, additional, Crisà, Elena, additional, Villa, Maria Rosaria, additional, Pezzullo, Luca, additional, Iovine, Mariolina, additional, Picardi, Marco, additional, Grimaldi, Francesco, additional, Monteverde, Maria, additional, and Pane, Fabrizio, additional

Published
2018
Full Text
View/download PDF

4. Initial Therapeutic Approach and Relationship with Clinical and Biological Characteristics at Diagnosis in 2418 Patients of the Registro Italiano Trombocitemie (RIT)

Author

Gugliotta, Luigi, primary, Iurlo, Alessandra, additional, Gugliotta, Gabriele, additional, Tieghi, Alessia, additional, Candoni, Anna, additional, Cattaneo, Daniele, additional, Ricco, Alessandra, additional, Lunghi, Monia, additional, Rumi, Elisa, additional, Scalzulli, Potito Rosario, additional, Dragani, Alfredo, additional, Antonioli, Elisabetta, additional, Martinelli, Vincenzo, additional, Randi, Maria Luigia, additional, Maschio, Nilla, additional, De Biasi, Ercole, additional, Appolloni, Viviana, additional, Cantore, Nicola, additional, Palmieri, Raffaele, additional, Santoro, Cristina, additional, Polverelli, Nicola, additional, Rago, Angela, additional, Cacciola, Rossella R, additional, Villa, Maria Rosaria, additional, Codeluppi, Katia, additional, Pierri, Ivana, additional, Fama, Angelo, additional, Piccin, Andrea, additional, Martino, Bruno, additional, Vianelli, Nicola, additional, Rupoli, Serena, additional, Santoro, Umberto, additional, Miglio, Rossella, additional, Monari, Paola, additional, and Mazzucconi, Maria Gabriella, additional

Published
2014
Full Text
View/download PDF

5. Bendamustine in Combination with Rituximab for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients: An Italian Retrospective Multicentre Study

Author

Gentile, Massimo, primary, Ciolli, Stefania, additional, Molica, Stefano, additional, Di Renzo, Nicola, additional, Selleri, Carmine, additional, Villa, Maria Rosaria, additional, De Paolis, Maria Rosaria, additional, Scortechini, Ilaria, additional, Giannotta, Angela, additional, Minoia, Carla, additional, Rago, Angela, additional, Boncompagni, Riccardo, additional, Bonanno, Vincenza, additional, Levato, Luciano, additional, Musso, Maurizio, additional, Mastrullo, Lucia, additional, Melpignano, Angela, additional, Murru, Roberta, additional, Angelucci, Emanuele, additional, Tarantini, Giuseppe, additional, Caparrotti, Giuseppe, additional, Guarini, Attilio, additional, Ferrara, Felicetto, additional, Cimino, Giuseppe, additional, Zinzani, Pier Luigi, additional, and Morabito, Fortunato, additional

Published
2014
Full Text
View/download PDF

6. Thrombosis History and Relationship With Low Thrombocytosis, Leukocytosis, and Other Characteristics At Diagnosis In 977 Essential Thrombocythemia Patients A Multivariate Analysis Of The Registro Italiano Trombocitemie (RIT)

Author

Gugliotta, Luigi, primary, Iurlo, Alessandra, additional, Tieghi, Alessia, additional, Gugliotta, Gabriele, additional, Candoni, Anna, additional, Rumi, Elisa, additional, Antonioli, Elisabetta, additional, Ricco, Alessandra, additional, Lunghi, Monica, additional, Scalzulli, Rosario Potito, additional, Scortechini, Anna Rita, additional, Codeluppi, Katia, additional, Martino, Bruno, additional, Dragani, Alfredo, additional, Patriarca, Andrea, additional, Martinelli, Vincenzo, additional, Battipaglia, Giorgia, additional, Randi, Maria Luigia, additional, Cosi, Elisabetta, additional, Liberati, Anna Marina, additional, Appolloni, Viviana, additional, Maschio, Nilla, additional, Mastrullo, Lucia, additional, Villa, Maria Rosaria, additional, Esposito, Maria Rosaria, additional, Cantore, Nicola, additional, Palmieri, Fausto, additional, Langella, Maria, additional, Rivellini, Flavia, additional, Mazzucconi, Maria Gabriella, additional, Santoro, Cristina, additional, De Biasi, Ercole, additional, Rago, Angela, additional, Polverelli, Nicola, additional, Spedini, Pierangelo, additional, Cacciola, Emma, additional, Cacciola, Rossella R, additional, Pierri, Ivana, additional, Mitsheunig, Laura, additional, Salvucci, Marzia, additional, Porretto, Ferdinando, additional, Piccin, Andrea, additional, Santoro, Umberto, additional, Gaidano, Gianluca, additional, Cimino, Giuseppe, additional, Lanza, Francesco, additional, Cortelezzi, Agostino, additional, Tagariello, Giuseppe, additional, Rupoli, Serena, additional, Specchia, Giorgina, additional, Passamonti, Francesco, additional, Vannucchi, Alessandro M., additional, Pane, Fabrizio, additional, Vianelli, Nicola, additional, Miglio, Rossella, additional, and Monari, Paola, additional

Published
2013
Full Text
View/download PDF

8. Biweekly Rituximab, Cyclophosphamide, Vincristine, Non-Pegylated Liposome-Encapsulated Doxorubicin (Myocet®) and Prednisone (R-COMP-14) as Induction Treatment in Poor R-IPI Risk Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Pre-Existing Heart Disease.

Author

Frigeri, Ferdinando, primary, Corazzelli, Gaetano, additional, Arcamone, Manuela, additional, Capobianco, Gaetana, additional, Lucania, Anna, additional, Becchimanzi, Cristina, additional, Marcacci, Gianpaolo, additional, Russo, Filippo, additional, Villa, Maria Rosaria, additional, Mastrullo, Lucia, additional, and Pinto, Antonio, additional

Published
2009
Full Text
View/download PDF

9. Cytoreductive Therapeutic Approach in the Essential Thrombocythemia (ET) Patients of the Registro Italiano Trombocitemia (RIT): Preliminary Data

Author

Gugliotta, Luigi, primary, Tieghi, Alessia, primary, Candoni, Anna, primary, Lunghi, Monia, primary, Gaidano, Gianluca, primary, Passamonti, Francesco, primary, Rumi, Elisa, primary, Dragani, Alfredo, primary, Radaelli, Franca, primary, Iurlo, Alessandra, primary, Specchia, Giorgina, primary, Carluccio, Paola, primary, Scalzulli, Potito Rosario, primary, Melillo, Lorella, primary, Martinelli, Vincenzo, primary, Ciancia, Rosanna, primary, Randi, Maria Luigia, primary, Vannucchi, Alessandro, primary, Antonioli, Elisabetta, primary, De Biasi, Ercole, primary, Palmieri, Fausto, primary, Latagliata, Roberto, primary, Santoro, Cristina, primary, Liberati, Anna Marina, primary, Gubbiotti, Marta, primary, Rupoli, Serena, primary, Scortechini, Anna Rita, primary, Villa, Maria Rosaria, primary, Cacciola, Rossella R, primary, Cacciola, Emma, primary, Pierri, Ivana, primary, Salvucci, Marzia, primary, Cristofalo, Claudio, primary, Cilloni, Daniela, primary, Vianelli, Nicola, primary, Federici, Augusto B., primary, Falanga, Anna, primary, and Ruggeri, Marco, primary

Published
2008
Full Text
View/download PDF

10. Prognostic role of translocator protein and oxidative stress markers in chronic lymphocytic leukemia patients treated with bendamustine plus rituximab.

Author

DE ROSA, ANIELLO, ZAPPAVIGNA, SILVIA, VILLA, MARIA ROSARIA, IMPROTA, SALVATORE, CESARIO, ELENA, MASTRULLO, LUCIA, CARAGLIA, MICHELE, and STIUSO, PAOLA

Subjects
MITOCHONDRIAL membranes, TRANSLOCATOR proteins, APOPTOSIS, CELL proliferation, BIOSYNTHESIS, IMMUNOREGULATION
Abstract

Principally located in the outer mitochondrial membrane, the translocator protein (TSPO) is an 18-kDa transmembrane protein that is a key component of the mitochondrial permeability transition pore. TSPO is associated with a number of biological processes, including apoptosis, the regulation of cellular proliferation, porphyrin transport and heme biosynthesis, immunomodulation, anion transport and the regulation of steroidogenesis. Thus, numerous studies have proposed TSPO as a promising target for novel therapeutic agents, particularly for the treatment of cancer. In the present study, the response of 30 consecutive chronic lymphocytic leukemia (CLL) patients to bendamustine and rituximab treatment was evaluated according to TSPO expression levels. Furthermore, thiobarbituric acid reactive substances (TBARS) and nitric oxide (NO) levels, as well as caspase-3 activity were determined. Compared with the lymphocytes of healthy donors, the 30 consecutive CLL patients exhibited increased TSPO expression levels, decreased TBARS and NO levels and reduced caspase-3 activity. Six months after the treatment commenced, the TSPO/mitochondria ratio resembled that of the healthy controls in 24/30 CLL patients. In addition, an increase in TBARS and NO levels, two markers of oxidative stress, and a potentiation of caspase-3 activity in all responder patients was observed. Notably, the six patients who appeared to be resistant to treatment also displayed higher TSPO levels, and lower caspase-3 activity and TBARS levels. These data indicate that TSPO expression may be a molecular prognostic factor in CLL patients. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

11. The Registro Italiano Trombocitemie (GIMEMA Project): Preliminary Analysis of the First 801 Enrolled Patients.

Author

Gugliotta, Luigi, primary, Tieghi, Alessia, additional, Gaidano, Gianluca, additional, Franceschetti, Silvia, additional, Specchia, Giorgina, additional, Carluccio, Paola, additional, Mazzucconi, Maria Gabriella, additional, Santoro, Cristina, additional, Dragani, Alfredo, additional, Ciancia, Rosanna, additional, Candoni, Anna, additional, Palmieri, Fausto, additional, Rumi, Elisa, additional, Antonioli, Elisabetta, additional, Villa, Maria Rosaria, additional, Cilloni, Daniela, additional, Federici, Augusto, additional, Vianelli, Nicola, additional, Radaelli, Franca, additional, Randi, Maria Luigia, additional, Scalzulli, Potito, additional, Melillo, Lorella, additional, Cacciola, Emma, additional, Cacciola, Rossella, additional, and Gobbi, Marco, additional

Published
2006
Full Text
View/download PDF

12. IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy

Author

Annarita Tagliaferri, Angelo Claudio Molinari, Flora Peyvandi, Antonio Coppola, Francesco Demartis, Chiara Biasoli, Alessandra Borchiellini, Dorina Cultrera, Raimondo De Cristofaro, Filomena Daniele, Paola Giordano, Emanuela Marchesini, Maurizio Margaglione, Renato Marino, Berardino Pollio, Paolo Radossi, Cristina Santoro, Rita Carlotta Santoro, Sergio Siragusa, Gianluca Sottilotta, Alberto Tosetto, Lydia Piscitelli, Maria Rosaria Villa, Ezio Zanon, Adele Finardi, Irene Schiavetti, Daniella Vaccari, Giancarlo Castaman, Tagliaferri, Annarita, Molinari, Angelo Claudio, Peyvandi, Flora, Coppola, Antonio, Demartis, Francesco, Biasoli, Chiara, Borchiellini, Alessandra, Cultrera, Dorina, De Cristofaro, Raimondo, Daniele, Filomena, Giordano, Paola, Marchesini, Emanuela, Margaglione, Maurizio, Marino, Renato, Pollio, Berardino, Radossi, Paolo, Santoro, Cristina, Santoro, Rita Carlotta, Siragusa, Sergio, Sottilotta, Gianluca, Tosetto, Alberto, Piscitelli, Lydia, Villa, Maria Rosaria, Zanon, Ezio, Finardi, Adele, Schiavetti, Irene, Vaccari, Daniella, and Castaman, Giancarlo

Subjects
ABR, Trough levels, annual consumption, extended half-life FIX, infusion frequency, real life, Hematology, General Medicine, Genetics (clinical)
Abstract

Introduction: Factor IX replacement therapy is used for treatment and prophylaxis of bleeding in haemophilia B. rIX-FP is an extended half-life albumin-fusion protein, which, in clinical studies, has demonstrated prolonged dosing intervals up to 21 days for routine prophylaxis, providing therapeutic benefit.Aims: To describe dosing frequency and consumption (primary endpoint), efficacy and safety of rIX-FP treatment during routine clinical practice in Italy.Methods: Patients with moderate/severe haemophilia B on prophylaxis with rIX-FP for >= 6 months, were enrolled in this observational study from October 2017 to February 2019 and followed-up for 2 years. Descriptive analysis included prospective and retrospective data (12 months prior to switching to rIX-FP).Results: Data were collected from 59 male patients (median age 30.1 years) enrolled by 23 Italian centres. Of them, 50 were on prophylaxis during the entire observation period and completed the study. The infusion frequency changed from 2-3 times/week in 86.0% of patients with previous treatment, to less than once a week in 84.0% of patients treated with rIX-FP at the 2nd-year fol low-up. The annual number of infusions decreased by about 70%, whereas the mean FIX activity trough level increased from 3.8% to 14.4% (mean > 10% in all the infusion regimens). Median Annualised Bleeding Rate of .0 was achieved across all prophylaxis regimens. Subjects with zero bleedings increased from 66.0% to 78.0% with rIX-FP.Conclusion: Treatment with rIX-FP reduced infusion frequency, while providing higher FIX trough levels with substantial benefit in terms of annualised bleeding rate and a good safety profile.

Published
2022

13. The Fcp1-Wee1-Cdk1 axis affects spindle assembly checkpoint robustness and sensitivity to antimicrotubule cancer drugs

Author

S Improta, L Del Vecchio, Luca Palazzo, Domenico Grieco, M.R. Villa, Maddalena Raia, Francesca D'Alessio, R Della Monica, Roberta Visconti, Visconti, Roberta, DELLA MONICA, Rosa, Palazzo, Luca, D'Alessio, F., Raia, M., Improta, S., Villa, MARIA ROSARIA, DEL VECCHIO, Luigi, and Grieco, Domenico

Subjects
Adult, Antineoplastic Agents, Cell Cycle Proteins, Polo-like kinase, Spindle Apparatus, Biology, Microtubules, Chromosome segregation, Young Adult, Cyclin-dependent kinase, Cell Line, Tumor, Neoplasms, CDC2 Protein Kinase, Phosphoprotein Phosphatases, Humans, cell cycle, spindle assembly checkpoint, mitosis, taxane, vinca alkaloids, Mitosis, Molecular Biology, Original Paper, Nuclear Proteins, Cell Biology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein-Tyrosine Kinases, Cyclin-Dependent Kinases, Cell biology, Spindle apparatus, Wee1, Spindle checkpoint, Mitotic exit, biology.protein, M Phase Cell Cycle Checkpoints, HeLa Cells
Abstract

To grant faithful chromosome segregation, the spindle assembly checkpoint (SAC) delays mitosis exit until mitotic spindle assembly. An exceedingly prolonged mitosis, however, promotes cell death and by this means antimicrotubule cancer drugs (AMCDs), that impair spindle assembly, are believed to kill cancer cells. Despite malformed spindles, cancer cells can, however, slip through SAC, exit mitosis prematurely and resist killing. We show here that the Fcp1 phosphatase and Wee1, the cyclin B-dependent kinase (cdk) 1 inhibitory kinase, play a role for this slippage/resistance mechanism. During AMCD-induced prolonged mitosis, Fcp1-dependent Wee1 reactivation lowered cdk1 activity, weakening SAC-dependent mitotic arrest and leading to mitosis exit and survival. Conversely, genetic or chemical Wee1 inhibition strengthened the SAC, further extended mitosis, reduced antiapoptotic protein Mcl-1 to a minimum and potentiated killing in several, AMCD-treated cancer cell lines and primary human adult lymphoblastic leukemia cells. Thus, the Fcp1-Wee1-Cdk1 (FWC) axis affects SAC robustness and AMCDs sensitivity.

Published
2014

14. Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation).

Author

Camera A, Volpicelli M, Villa MR, Risitano AM, Rossi M, and Rotoli B

Subjects
Acute Disease, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Fatal Outcome, Humans, Male, Remission Induction methods, Erythropoietin administration & dosage, Granulocyte Colony-Stimulating Factor administration & dosage, Leukemia, Erythroblastic, Acute drug therapy
Abstract

Alternative therapeutic approaches with low dose chemotherapy and differentiative-maturative treatment by growth factors are under consideration for elderly patients with acute leukemia. Two patients with AML-M6 with maturation, one refractory to standard chemotherapy and the other ineligible for cytoxic treatment, obtained complete remission from leukemia using high dose recombinant erythropoietin and granulocyte colony-stimulating factor.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results